



# Engineering the Future of Neurotechnology

Our mission is simple: We want people with neurological disorders to walk, talk, see, hear, and feel again.

This is the most exciting time in the history of neuroscience—and Blackrock Neurotech is on the precipice. As the global leader in brain-computer interface (BCI technology), we pioneered the implantable neurotech space with brain tech that restores function in people with paralysis and neurological disorders like ALS and epilepsy.

Our BCI technology is in humans now - our patients have been able to move and feel again, type, make music, even create art.

In addition to BCIs, we build implantable tools and microelectronics that diagnose and treat neurological disorders as well as research tools that have empowered thousands of published studies and groundbreaking innovations at hundreds of institutions around the world.

# ACCOMPLISHMENTS & ADVANCEMENTS

## 32

### Patients

Of the 35 people worldwide with BCIs, 32 have been implanted with Blackrock technology.



### The Gold Standard

Our flagship BCI product, the NeuroPort Array, is the only FDA-cleared platform used in BCI applications for movement disorders.

## 8 Years Running

Our BCI is the longest chronic implant in humans, with nearly 8 years chronically implanted.



### Thousands of studies and hundreds of partners

Blackrock's research tools empower more than 500 institutional partners and customers, including Johns Hopkins, Brown, Caltech, University of Pittsburgh, and we have an international presence with more than two hundred top research and clinical institutions globally.



### The first commercially available BCI

The FDA granted Breakthrough Status designation for our MoveAgain BCI, which is expected to become commercially available by the end of 2022.



### 10,000-20,000 Patient Days

Our BCI has been in patients for vastly more time than our only competitor, resulting in better data and more patient feedback to guide product development.



*We see it as Blackrock's responsibility to ensure clinical translation of all the achievements made in the lab these past few decades. Patients are ready – and so are we.*

**Marcus Gerhardt, CEO**

## Company Fact Sheet

<b>Headquarters</b>	Salt Lake City, UT
<b>Founded</b>	2008
<b>Leadership</b>	Marcus Gerhardt, Co-Founder, CEO Florian Solzbacher, Co-Founder, President
<b>What We Do</b>	Blackrock Neurotech a privately held company, is a global leader in brain-computer interface (BCI) technology. In addition, the company produces the most advanced platform tools for neuroscience, neural engineering and neuroprosthetics research & clinical communities worldwide. Our technology has empowered pioneering research at more than 500 leading institutions worldwide.
<b>Key Products</b>	Blackrock's first commercial BCI product, the MoveAgain system, is expected to be available in 2023. The system is built on the NeuroPort Array, Blackrock's flagship electrode array, widely considered the gold-standard electrode for recording and stimulating the brain. In addition, the company has created the world's largest portfolio of turnkey solutions that facilitate acquisition, processing, and analysis of electrical signals recorded from the brain and peripheral nervous system for use in rodent, primate, and human research experiments. Our fully-integrated systems range from 'out-of-the-box' solutions to fully customized systems where technical support is provided from the start to the end of an experiment.
<b>Product Highlights</b>	Blackrock Neurotech has a robust portfolio of cleared medical devices and neurotechnology products and is one of the top choices for human research projects. Products include the Utah Array, wireless headstages, and DAQs.
<b>Strategic Partnerships</b>	The University of Utah, Johns Hopkins Applied Physics Lab, Stanford University, Brown University, MIT, PhenoSys, Defense Advanced Research Projects Agency, DARPA HAPTIX, NIH
<b>Media Contact</b>	Jessica Fossmeier +1 (520) 780-8299 <a href="mailto:jfossmeier@blackrockneuro.com">jfossmeier@blackrockneuro.com</a>

## **Executive Management Team**

**Marcus Gerhardt**  
*Co-Founder, CEO*

Marcus Gerhardt co-founded Blackrock in 2008 with Professor Florian Solzbacher, a lifelong friend and colleague, with the initial mission of restoring function and movement in paralyzed patients. Since that time, the two have expanded the clinical translations of neurotechnology, building BCIs that help patients walk, talk, feel, and move again.

A career entrepreneur and investment advisor focused on innovative technologies and alternative investment markets, Gerhardt has brought operational excellence and profitability to Blackrock, driven strategic investment into areas of potential growth and scaled the company to expand its portfolio of technologies. Gerhardt's vision for Blackrock is to utilize the company's vast experience in neuroscience technology to help the millions of people with neurological disorders gain independence.

In addition to his role as CEO, Gerhardt also serves as a Board Director of Blackrock Neuromed.

Gerhardt co-founded a number of companies prior to joining Blackrock Neurotech in 2008, including Mondus, a pioneering ecommerce platform and one of the leading frontier market asset managers in the Middle East. Leveraging his expertise in management and financing for SME high-tech enterprises, Gerhardt also founded BBI, an international consulting firm that advises technology companies on funding, commercialization, and growth strategies.

Gerhardt earned his MPhil from Oxford University and his MA in Management from the University of St. Andrews in the UK.

**Prof. Florian Solzbacher**  
*Co-Founder, Chairman & President*

A leading authority on chronically implantable sensors for electrophysiological and chemical biomarkers, Dr. Solzbacher serves as Director, Chair, and Advisor to a host of internationally renowned academic institutions, public-private partnerships, and innovative companies. As Chairman and President of Blackrock Neurotech, Dr. Solzbacher drives the technological vision for the company, with a focus on restorative tech for neurological conditions.

Among his varied leadership positions, Dr. Solzbacher serves as Director of the newly established Center for Engineering Innovation at the University of Utah, Co-Director of the Utah Nanotechnology Institute, and holds faculty appointments in Electrical and Computer Engineering, Materials Science, and Bioengineering at the University of Utah. His research focuses on harsh environment microsystems and materials, including implantable, wireless microsystems for biomedical and healthcare applications, and on high-temperature and harsh environment compatible micro sensors.

Co-founder of several companies including Blackrock Neuromed, SentioMed, and First Sensor Technology, Dr. Solzbacher is also a member of the Governing Authority Board for the Utah Science Technology and Research Initiative (USTAR). He was director of the Utah Nanofabrication Laboratory until 2013 and serves on a number of company and public-private partnership advisory and reviewer boards in Europe and the U.S., including the German Excellence Initiative, the European Research Council ERC, The Utah Governor's Science and Technology advisory board and NIH/NINDS Neural Interfaces Conference. He is author of more than 190 journal and conference publications, five book chapters and 22 invention disclosures, pending patents, or patents.

Dr. Solzbacher received his M.Sc. EE from the Technical University Berlin in 1997 and his Ph.D. from the Technical University Ilmenau in 2003.

**Tim Sievers**  
*Board Member*

Dr. Tim Sievers is founder and CEO of Deposit Solutions. He is member of well-recognized committees such as the FinTech Committee of the Federal Ministry of Finance and the Digital Banking Project Committee of the Association of German Banks. Prior to founding Deposit Solutions in 2011, Tim Sievers successfully built up technology companies and worked in private equity. He holds a doctorate in Economics from the University of Hamburg, a M.Sc. in Economics from the London School of Economics and Political Science and a M.A. in Politics, Philosophy and Economics from the University of Oxford.

**Christian Angermayer**  
*Board Member*

Christian Angermayer is an entrepreneur, investor, and film enthusiast. He is the founder of Apeiron Investment Group, his family office and merchant banking business. Apeiron focuses on investments in biotech, fintech & crypto and deep tech companies. Apeiron completes deals across the entire lifecycle and balance sheet of a company, from non-listed seed/start-up investments to larger scale restructuring and special situations deals.

Passionate about the arts and film, Christian has (executive) produced 21 feature films including critically acclaimed movies like Filth, Aspern Papers and Hector and the Search for Happiness. He is the largest shareholder of DEAG, one of the largest live entertainment companies in Europe. Christian has a unique art collection centered around the theme "Psychedelics / Entheogens".

With his biotech company ATAI Life Sciences, Christian has the ambitious goal to find cures for various mental health issues like depression, anxiety, addiction, and PTSD by bringing back so-called psychedelics like "magic mushrooms" and DMT into the legal realm as powerful medical treatment.

In addition to his entrepreneurial activities, Christian places great value on social, political, and societal commitments. He is a Young Global Leader of the World Economic Forum, a member of the Presidential Advisory Council of His Excellency President Paul Kagame of Rwanda and a member of the Milken



Institute Young Leaders Circle. Christian's "Angermayer Policy and Innovation Forum" convenes several times a year Heads of State, leading politicians, artists, investors, and scientists to discuss crucial topics and issues.

UK Newspaper Sunday Times ranks Christian among the 1,000 richest people living in the United Kingdom with an estimated net worth of approx. USD 700 million.

**TS Lau**  
*Co-Founder  
& Non-Executive Director*

TS Lau is Founder, Chairman, and CEO of Kim Ann Engineering Pte Ltd, a leading specialty metals business in Singapore.